Bone marrow‐derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy—A meta‐analysis

Wen, Yanting; Ding, Jingjing; Zhang, Bin; Gao, Qian

doi:10.1111/eci.12894

Cited by 13 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most trials reported no or did not report procedure-related complications such as arrhythmia, stroke, and myocardial infarction. These results correlate well with the previous meta-analysis conducted in 2016 [23].…”

Section: Resultssupporting

confidence: 92%

Efficacy and Safety of Stem Cell Therapy in Advanced Heart Failure Patients: A Systematic Review with a Meta-analysis of Recent Trials Between 2017 and 2019

Jayaraj

Janapala

Qaseem

et al. 2019

Cureus

View full text Add to dashboard Cite

ObjectiveThe effects of stem cell therapy in patients with advanced heart failure is an ongoing debate. This study aimed to assess the effectiveness and safety of stem cell therapy plus the standard of care as compared to the placebo plus the standard of care in advanced heart failure patients.MethodsA comprehensive keyword search of PubMed between 2017 and 2019 was performed to extract trials conducted with stem cell therapy controlled with placebo in advanced heart failure. We included randomized controlled trials (RCTs) with data on safety and efficacy in patients with advanced heart failure after stem cell transplantation.ResultsSix RCTs, consisting of 569 patients, were selected. Three-hundred sixty-seven (367) out of 369 participants from the eligible four out of six RCTs were included for efficacy analysis, as we lost two patients from the final analysis due to early death. Five-hundred twenty-six (526) out of 527 participants from the eligible five out of six RCTs were included for safety analysis, as we lost one patient from the final analysis for not being able to receive the intervention. Stem cell transplantation significantly improved left ventricular ejection fraction (LVEF) by 4.58% (95% CI: 3.73-5.43%; p = 0.00001), improved left ventricular end-systolic volume (LVESV) by -5.18 ml (95% CI: -9.74 to -0.63 ml; p =0.03), and there was no difference in the risk of all-cause mortality (OR 0.97; 95% CI: 0.52 to 1.78%; p = 0.91). The above results correlate with the previous meta-analysis data conducted in 2016.ConclusionsThis meta-analysis provided the cumulative efficacy and safety results of stem cell transplantation in advanced heart failure based on recent RCTs. The above results suggest that stem cell therapy was associated with a moderate improvement in LVEF, and the safety analysis indicates no increased risk of mortality in patients with advanced heart failure. This meta-analysis recommends conducting more RCTs comparing stem cell transplantation and placebo with a larger patient population and longer follow-up.

show abstract

Section: Resultssupporting

confidence: 92%

Efficacy and Safety of Stem Cell Therapy in Advanced Heart Failure Patients: A Systematic Review with a Meta-analysis of Recent Trials Between 2017 and 2019

Jayaraj

Janapala

Qaseem

et al. 2019

Cureus

View full text Add to dashboard Cite

show abstract

“…However, there were many meta-analyses and systematic reviews that compared the effectiveness of BMC treatment method between a variety of patients with heart failure, either before and after treatment or between the cases and controls. The results of such studies indicate the superiority and effectiveness of BMC method, especially in the mortality index and LVEF index, when comparing patients before and after the treatment or when comparing the cases with the controls ( 21 , 23 , 35 , 36 ). It is in line with the results of this study, which showed the medical effectiveness of BMC treatment method, as compared with the placebo.…”

Section: Discussionmentioning

confidence: 96%

Evaluation of the effectiveness of infusion of bone marrow derived cell in patients with heart failure: A network meta-analysis of randomized clinical trials and cohort studies

Lotfi

Jafari

Hemami

et al. 2020

mjiri

View full text Add to dashboard Cite

“…Although there are still considerable dispute in the clinical effect based on stem cells therapy, the positive results obtained in the repair of damaged myocardium indicated it has become a promising candiadate [18]. In fact, diverse stem cells have been identified and applied to the regeneration medicine including bone marrow-derived mononuclear cell (BM-MNCs) [19] and umbilical cord blood-derived stem cells (UCB-SCs) [20]. Studies have shown pluripotent stem cells (PSCs) are precursors of monopotent stem cells during organ/tissue rejuvenation and a source of these cells in emergency situations when organs are damaged (e.g., A rare Sca1 + Lin − CD45 − SCs population were initially identified, isolated from adult mice via fluorescence activated cell sorting and named as very small embryoniclike stem cells (VSELs) [22].…”

Section: Discussionmentioning

confidence: 99%

Histone demethylase KDM5B catalyzed H3K4me3 demethylation to promote differentiation of bone marrow mesenchymal stem cells into cardiomyocytes

Wang

Zhong

2022

Mol Biol Rep

View full text Add to dashboard Cite

Background Studies have shown that histone H3 methylation is involved in regulating the differentiation of Bone Marrow Mesenchymal Stem Cells (BMSCs). KDM5B can specifically reduce the level of histone 3 lysine 4 trimethylation (H3K4me3), thereby activating the expression of related genes and participating in biological processes such as cell differentiation, embryonic development and tumor formation. Whether KDM5B is involved in the regulation of BMSCs differentiation into cardiomyocytes through the above manner has not been reported. Objective To investigate the effect of KDM5B on the induction and differentiation of swine BMSCs into myocardial cells in vitro. Methods Swine bone marrow BMSCs were isolated and cultured, and the overexpression, interference expression and blank vector of KMD5B were constructed and transfected by lentivirus. BMSCs was induced to differentiate into cardiomyocytes by 5-azacytidine (5-AZA) in vitro, and the differentiation efficiency was compared by immunofluorescence, RT-PCR, Western Blot and whole-cell patch clamp detection. Result Compared with the control group, the expression levels of histone H3K4me3 and pluripotency gene Nanog in KDM5B overexpression group were significantly decreased, while the expression level of key myocardial gene HCN4 and myocardial marker gene α-Actin and cTNT were significantly increased, and the Na+ current density on the surface of differentiated myocardial cell membrane was significantly increased. Meanwhile, the corresponding results of the KDM5B silent expression group were just opposite. Conclusions It indicated that enhanced KDM5B expression could promote the differentiation of BMSCs into cardiomyocytes and improve the differentiation efficiency by controlling H3K4 methylation levels.

show abstract

Bone marrow‐derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy—A meta‐analysis

Cited by 13 publications

References 39 publications

Efficacy and Safety of Stem Cell Therapy in Advanced Heart Failure Patients: A Systematic Review with a Meta-analysis of Recent Trials Between 2017 and 2019

Efficacy and Safety of Stem Cell Therapy in Advanced Heart Failure Patients: A Systematic Review with a Meta-analysis of Recent Trials Between 2017 and 2019

Evaluation of the effectiveness of infusion of bone marrow derived cell in patients with heart failure: A network meta-analysis of randomized clinical trials and cohort studies

Histone demethylase KDM5B catalyzed H3K4me3 demethylation to promote differentiation of bone marrow mesenchymal stem cells into cardiomyocytes

Contact Info

Product

Resources

About